The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Liraglutide and Renal Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The LEADER and REWIND trials also report a greater than 20% reduction in the risk of developing new macroalbuminuria, along with favourable trends in other clinically relevant adverse renal outcomes. 26,27”
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95-100).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs have also been shown to improve kidney outcomes (104-109).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [106]
In the citing paper
“However, the composite kidney outcomes in these trials were evaluated as secondary outcomes, and the reported effects were largely driven by a lower risk of new-onset macroalbuminuria. 23-25”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [24]
In the citing paper
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [28]
In the citing paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Cited by
Sorted by citations
Items 301–400 of 1,000
SKOLNIK, N., & Style, A. J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01050-w · Cited by 40
Management of traditional risk factors for the development and progression of chronic kidney disease
Lo, R. H., Narasaki, Y., Lei, S., & Rhee, C. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad101 · Cited by 40
Current understanding of the structure and function of family B GPCRs to design novel drugs
Karageorgos, V., Venihaki, M., Sakellaris, S., Pardalos, M., Kontakis, G. M., Matsoukas, M., Gravanis, A., Margioris, A. N., & Liapakis, G. (2018) · HORMONES · doi:10.1007/s42000-018-0009-5 · Cited by 40
Fadini, G. P., Solini, A., Manca, M. L., Penno, G., Gatti, A., Anichini, R., Prato, S. D., Avogaro, A., & For The DARWIN‐T2D Network (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13508 · Cited by 40
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 40
Dalbøge, L. S., Christensen, M. S., Madsen, M. R., Secher, T., Endlich, N., Drenić, V., Manresa-Arraut, A., Hansen, H. H., Rune, I., Fink, L. N., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071661 · Cited by 40
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 39
Lee, B. S., Holstein‐Rathlou, N., Sosnovtseva, O. V., & Sørensen, C. M. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00147.2023 · Cited by 39
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 39
Abdelhafiz, A. H., & Sinclair, A. J. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107639 · Cited by 39
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
Epigenetic modification in diabetic kidney disease
Liu, Z., Liu, J., Wang, W., An, X., Luo, L., Yu, D., & Sun, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1133970 · Cited by 38
Vest, A. R., Cherikh, W. S., Noreen, S. M., Stehlik, J., & Khush, K. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003647 · Cited by 38
de Gaetano, M., McEvoy, C. M., Andrews, D. C., Cacace, A., Hunter, J., Brennan, E. P., & Godson, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01488 · Cited by 38
Yang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.003 · Cited by 37
van der Aart‐van der Beek, A. B., Clegg, L. E., Penland, R. C., Boulton, D. W., Sjöström, C. D., Mentz, R. J., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14175 · Cited by 37
Dong, S., & Sun, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032199 · Cited by 37
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37
Yaseen, A., & Lahiri, S. W. (2023) · Clinical Diabetes · doi:10.2337/cd22-0100 · Cited by 37
Chaudhry, K., & Karalliedde, J. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15765 · Cited by 37
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Mirabelli, M., CHIEFARI, E. D., Tocci, V., Caroleo, P., Giuliano, S., Greco, E. A., Luque, R. M., Puccio, L., FOTI, D. P., Aversa, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050985 · Cited by 37
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 36
Hasan, A. A., von Websky, K., Reichetzeder, C., Tsuprykov, O., Gaballa, M. M. S., Guo, J., Zeng, S., Delić, D., Tammen, H., Klein, T., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.010 · Cited by 36
Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Márquez, D. F., Ruiz‐Hurtado, G., Segura, J., & Ruilope, L. M. (2019) · F1000Research · doi:10.12688/f1000research.17212.1 · Cited by 36
Yoo, H., Choo, E., & Lee, S. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00605-5 · Cited by 36
Tong, L., & Adler, S. G. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457397 · Cited by 36
Diallo, A., Carlos‐Bolumbu, M., & Galtier, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02154-4 · Cited by 35
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial
Scirica, B. M., Bohula, E. A., Dwyer, J. P., Qamar, A., Inzucchi, S. E., McGuire, D. K., KEECH, A. C., Smith, S. R., Murphy, S. A., Im, K., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038341 · Cited by 35
Nonproteinuric progressive diabetic kidney disease
Zoccali, C., & Mallamaci, F. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000489 · Cited by 35
Major adverse renal events (MARE): a proposal to unify renal endpoints
Prischl, F. C., Rossing, P. R., Bakris, G. L., Mayer, G. J., & Wanner, C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz212 · Cited by 35
Renal protection with glucagon-like peptide-1 receptor agonists
Vitale, M., Haxhi, J., Cirrito, T., & Pugliese, G. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.018 · Cited by 35
How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sánchez-Fructuoso, A. I., de la Nieta, M. D. S., Agraz, I., & Soler, M. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112505 · Cited by 35
Yuan, D., Sharma, H., Krishnan, A., Vangaveti, V., & Malabu, U. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14776 · Cited by 35
Tang, Y., Zhang, L., Zeng, Y., Wang, X., & Zhang, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016639 · Cited by 35
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Giglio, R. V., Patti, A. M., Rizvi, A. A., Stoian, A. P., Ciaccio, M., Παπάνας, Ν., Janež, A., Sönmez, A., Banach, M., Sahebkar, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020291 · Cited by 35
Advances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
Sivalingam, S., Wasehuus, V. S., Rotbain Curovic, V., Blond, M. B., Hansen, T. W., Persson, F., & Rossing, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15287 · Cited by 34
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 34
Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial
Nauck, M. A., Buse, J. B., Mann, J. F. E., Pocock, S., Bosch‐Traberg, H., Frimer‐Larsen, H., Ye, Q., & Gray, A. M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13547 · Cited by 34
Self-citationAmod, A., Buse, J. B., McGuire, D. K., Pieber, T. R., Pop‐Busui, R., Pratley, R. E., Zinman, B., Hansen, M. B., Jia, T., Mark, T., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00715-x · Cited by 34
Self-citationCherney, D. Z. I., Hadjadj, S., Lawson, J., Mosenzon, O., Tuttle, K. R., Vrhnjak, B., Rasmussen, S., & Bain, S. C. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.07.167 · Cited by 34
Self-citationMechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 33
Jia, M., Lv, X., Zhu, T., Shen, J.-C., Liu, W., & Yang, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06492-7 · Cited by 33
Sirtuin 3 in renal diseases and aging: From mechanisms to potential therapies
Xuan, P., Ni, H., Kuang, B., Wang, Z., Hou, S., Gu, S., & Gong, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107261 · Cited by 33
Stenberg, E., Ottosson, J., Cao, Y., Sundbom, M., & Näslund, E. B. (2024) · British journal of surgery · doi:10.1093/bjs/znae221 · Cited by 33
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Avgoustou, E., Tzivaki, I., Diamantopoulou, G., Zachariadou, T., Avramidou, D., Dalopoulos, V., & Skourtis, A. (2025) · Diagnostics · doi:10.3390/diagnostics15020169 · Cited by 33
Packer, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1185 · Cited by 33
Management of type 2 diabetes: consensus of diabetes organizations
Quattrocchi, E. J., Goldberg, T., & Marzella, N. (2020) · Drugs in Context · doi:10.7573/dic.212607 · Cited by 33
Shaping Up Mitochondria in Diabetic Nephropathy
Mise, K., Galvan, D. L., & Danesh, F. R. (2020) · Kidney360 · doi:10.34067/kid.0002352020 · Cited by 33
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 33
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01877-6 · Cited by 33
Acute kidney injury and disease: Long‐term consequences and management
Rangaswamy, D., & Sud, K. (2018) · Nephrology · doi:10.1111/nep.13408 · Cited by 33
Kaneko, S., Ueda, Y., & Tahara, Y. (2018) · European Surgical Research · doi:10.1159/000494768 · Cited by 32
Current Perspectives on Management of Type 2 Diabetes in Youth
Singhal, S., & Kumar, S. (2021) · Children · doi:10.3390/children8010037 · Cited by 32
Tuttle, K. R., Bain, S. C., Bosch‐Traberg, H., Khunti, K., Rasmussen, S., Sokareva, E., & Cherney, D. Z. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.028 · Cited by 32
Self-citationRenoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 32
Iacoviello, M., Gori, M., Grandaliano, G., Minutolo, R., Pitocco, D., & Trevisan, R. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1583702 · Cited by 32
Packer, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0648-x · Cited by 32
van Baar, M. J. B., van der Aart, A. B., Hoogenberg, K., Joles, J. A., Heerspink, H. J. L., & van Raalte, D. H. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865398 · Cited by 32
2019 Diabetes Atlas: Achievements and challenges in diabetes care in Taiwan
Hsu, C., Tu, S., & Sheu, W. H. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.06.018 · Cited by 32
Kashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 32
MicroRNA Expression Profiling in Diabetic Kidney Disease
Ishii, H., Kaneko, S., Yanai, K., Aomatsu, A., Hirai, K., Ookawara, S., & Morishita, Y. (2021) · Translational research · doi:10.1016/j.trsl.2021.05.008 · Cited by 32
Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
Hocher, B., & Tsuprykov, O. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.140 · Cited by 32
Zitman‐Gal, T., Einbinder, Y., Ohana, M., Katzav, A., Kartawy, A., & Benchetrit, S. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12891 · Cited by 32
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
Perkovic, V., Koitka‐Weber, A., Cooper, M. E., Schernthaner, G., Pfarr, E., Woerle, H. J., von Eynatten, M., & Wanner, C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz179 · Cited by 32
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31
Krisanapan, P., Sanpawithayakul, K., Pattharanitima, P., Thongprayoon, C., Miao, J., Mao, M. A., Suppadungsuk, S., Tangpanithandee, S., Craici, I. M., & Cheungpasitporn, W. (2024) · Diseases · doi:10.3390/diseases12010014 · Cited by 31
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Ali, M. M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. I. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 31
New insights in the treatment of DKD: recent advances and future prospects
Zhao, M., Cao, Y., & Ma, L. (2025) · BMC Nephrology · doi:10.1186/s12882-025-03953-3 · Cited by 31
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 31
de Cos, M., Xipell, M., García‐Herrera, A., Lledó, G. M., Guillén, E., Blasco, M., Espinosa, G., Cervera, R., & Quintana, L. F. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.103014 · Cited by 31
A promising outlook for diabetic kidney disease
Cooper, M. E., & Warren, A. M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0092-5 · Cited by 31
Bertoluci, M. C., Salles, J. E. N., Silva‐Nunes, J., Pedrosa, H. C., Moreira, R. O., Duarte, R., Carvalho, D. M., Trujilho, F. R., Raposo, J. F. C. D. S., Parente, E. B., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00551-1 · Cited by 31
Tanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 31
Wang, Y., He, W., Wei, W., Mei, X., Yang, M., & Wang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622737 · Cited by 30
Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub3 · Cited by 30
Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease
Vazquez, M., Oliver, G., Amarasingham, R., Sundaram, V., Chan, K. T. K., Ahn, C. W., Zhang, S., Bickel, P. E., Parikh, S. M., Wells, B. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311708 · Cited by 30
Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Yip, J., Chiang, G. S. H., Lee, I. C. J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L. Y.-T., Teo, D. W. X., Seah, G. T., & Lehming, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010364 · Cited by 30
der Beek, A. B. V. D. A., van Raalte, D. H., Guja, C., Hoogenberg, K., Suchower, L. J., Hardy, E., Sjöström, C. D., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14067 · Cited by 30
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Li, X., Song, Y., Guo, T., Xiao, G., & Li, Q. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101366 · Cited by 30
Hsiao, F., Yen, K., Chao, T., Chen, S., Chan, Y., & Chu, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac402 · Cited by 30
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 30
Xu, J., Kitada, M., & Koya, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165756 · Cited by 30
Wang, T., Ding, J., Cheng, X., Yang, Q., & Hu, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396656 · Cited by 29
Nakaguchi, H., Kondo, Y., Kyohara, M., Konishi, H., Oiwa, K., & Terauchi, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13270 · Cited by 29
Morieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s216054 · Cited by 29
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 29
Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications
Afşar, B., Hornum, M., Afşar, R. E., Ertuğlu, L. A., Ortíz, A., Covic, A. C., van Raalte, D. H., Cherney, D. Z. I., & Kanbay, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.016 · Cited by 29
Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Saisho, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.24 · Cited by 29
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
Vanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15967 · Cited by 28
Liraglutide relieves cardiac dilated function than DPP ‐4 inhibitors
Hiramatsu, T., Asano, Y., Mabuchi, M., Imai, K., Iguchi, D., & Furuta, S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13007 · Cited by 28
Mallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 28
Cao, H., Liu, T., Wang, L., & Ji, Q. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14702 · Cited by 28
Yanai, H., Hakoshima, M., Adachi, H., & Katsuyama, H. (2022) · Cardiology Research · doi:10.14740/cr1441 · Cited by 28
Sato, T., Azuma, Y., Ozone, C., Okazaki, M., Takeda, A., Okada, M., Futamura, K., Hiramitsu, T., Goto, N., Narumi, S., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad177 · Cited by 28
Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease
Wang, X., Zhang, H., Zhang, Q., Guan, M., Sheng, S., Mo, W., Zou, M., Li, J., Bi, J., Tang, X., et al. (2020) · American Journal of Nephrology · doi:10.1159/000510255 · Cited by 28
Metadata
- Authors
- Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 839-848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752707491
- Semantic Scholar
- e3932087f500b455476965939bdced15360eb028
- Cited by
- 1,253
- References
- 32
- Citations by year
- 2026: 99 · 2025: 116 · 2024: 121 · 2023: 131 · 2022: 134 · 2021: 161 · 2020: 180 · 2019: 139 · 2018: 152 · 2017: 20
- FWCI
- 106.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Novo Nordisk
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, renal outcomes, diabetic nephropathy, macroalbuminuria, end-stage renal disease, acute kidney injury, glucagon-like peptide-1 analogues, albuminuria, estimated glomerular filtration rate, cardiovascular risk, renal adverse effects, LEADER trial, cardiovascular outcomes, serum creatinine doubling, usual care
- MeSH terms
- Liraglutide, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Glucagon-Like Peptide 1, Intention to Treat Analysis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
